Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Long-Term Deferred Tax (2016 - 2024)

Guided Therapeutics (GTHP) has disclosed Long-Term Deferred Tax for 5 consecutive years, with $17.6 million as the latest value for Q4 2024.

  • Quarterly Long-Term Deferred Tax changed N/A to $17.6 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $17.6 million through Dec 2024, changed N/A year-over-year, with the annual reading at $17.6 million for FY2024, N/A changed from the prior year.
  • Long-Term Deferred Tax hit $17.6 million in Q4 2024 for Guided Therapeutics, down from $21.0 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $17.6 million in Q4 2024 to a low of $17.6 million in Q4 2024.